Apr 24, 2013

BIO Buzz Center with Ken Kelley, CEO, PaxVax

In an interview with BIO Buzz, Kenneth Kelley, PaxVax CEO, discusses how PaxVax is differentiating itself from other biotechnology companies and vaccine multinational companies as well as the company’s one-dose, oral cholera vaccine in development.


Apr 23, 2013

Your Views – The Double Bottom Line Dance

Kenneth Kelley, PaxVax CEO, writes about PaxVax’s double bottom line. The company explores all available avenues to funding and capital efficiency, while keeping investors satisfied with both financial and social returns.


Jun 1, 2012

Showcase Feature: Clinical Trial Solutions

Clinical trial management works to improve efficiencies, gain increased patient and investigator access, and better integrate R&D capabilities and solutions.


Mar 20, 2012

PaxVax Preps Cholera Vaccine For Phase III; H5N1 for Phase II

PaxVax prepares fast-acting cholera vaccine, PXVX-0200, for Phase III trials and influenza vaccine, H5N1, for Phase II trials.


Mar 20, 2012

PaxVax Submits IND for Refurbished Crucell One-Dose Oral Cholera Vaccine

The U.S. FDA accepts investigational new drug (IND) application from PaxVax for single-dose, oral cholera vaccine.


Mar 1, 2012

Modernizing Vaccine Production

The U.S. government invests in vaccine production technology to provide alternative flu vaccines that can be developed and delivered efficiently in the presence of biological threats.


Oct 10, 2010

NIH Funds Advanced Development of Three Biodefense Vaccines

The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health announces the decision to fund research on three vaccines to protect against emerging infectious diseases and biological threats.


3 of 3123